Search results
Results From The WOW.Com Content Network
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa).
mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (mTOR) (also known as the mechanistic target of rapamycin), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases ...
A big part of waste management deals with municipal solid waste, which is created by industrial, commercial, and household activity. [4] Waste management practices are not the same across countries (developed and developing nations); regions (urban and rural areas), and residential and industrial sectors can all take different approaches. [5]
The mammalian target of rapamycin (mTOR), [5] also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the MTOR gene. [6] [7] [8] mTOR is a member of the phosphatidylinositol 3-kinase-related kinase family of protein ...
WMP Waste Management Plan; WMPEG Waste Minimisation Performance and Efficiency Grant; WMS Waste Management Strategy; WRAP Waste and Resources Action Programme; WRATE Waste and Resources Assessment Tool for the Environment; WRG Waste Recycling Group; WRWA Western Riverside Waste Authority; WS2007 Waste Strategy for England 2007 (superseded by ...
Yoo, Young Ji; Hwang, Jae-yeon; Shin, Hea-luyung; Cui, Heqing; Lee, Jinwon; Yoon, Yeo Joon (26 November 2014). "Characterization of negative regulatory genes for the biosynthesis of rapamycin in Streptomyces rapamycinicus and its application for improved production". Journal of Industrial Microbiology & Biotechnology. 42 (1): 125–135.
NHS England has been criticised for delays in deciding on a policy for the prescription of everolimus in the treatment of Tuberous Sclerosis. 20 doctors addressed a letter to the board in support of the charity Tuberous Sclerosis Association saying " around 32 patients with critical need, whose doctors believe everolimus treatment is their best or only option, have no hope of access to funding.
For substances used in food prior to January 1, 1958, a grandfather clause allows experience based on common use in food to be used in asserting an ingredient is safe under the conditions of their intended use. [3] The FDA can also explicitly withdraw the GRAS classification, as it did for trans fat in 2015. [6]